You Are Preparing a Patient With Acute Coronary Syndrome ACS for Early Reperfusion Therapy: The Interventions Used, From First ECG to Cath Lab Handoff

Early reperfusion in acute coronary syndrome begins with a 12-lead ECG within 10 minutes of first medical contact, followed by aspirin, a P2Y12 inhibitor when indicated, anticoagulation, and a prompt handoff to the cath lab or fibrinolytic pathway. For ST-elevation myocardial infarction, the target is primary percutaneous coronary intervention within 90 minutes of first contact at a PCI-capable hospital, or 120 minutes if transfer is required. The interventions below cover the first 60 to 90 minutes of care, which is where outcomes are won or lost.

There is a boundary here worth stating up front. This article describes the standard pre-reperfusion bundle as taught by the American Heart Association and American College of Cardiology and by the European Society of Cardiology. It is educational, not a protocol for any single hospital, and every patient's situation needs a locally credentialed clinician making the call.

The 10-Minute ECG and Its Immediate Consequences

The ECG is the first intervention that changes the plan, and the clock starts when the patient or EMS first makes contact, not when the emergency department doors open.

A 12-lead tracing obtained and interpreted within 10 minutes of arrival is the standard benchmark in both the AHA/ACC and ESC frameworks. If the first ECG is nondiagnostic but symptoms continue, repeat tracings every 15 to 30 minutes, and add posterior leads (V7–V9) or right-sided leads (V4R) when the pattern suggests an occlusion that standard leads miss. Right-sided leads matter for inferior infarcts because RV involvement changes fluid and nitrate management.

Posterior and right ventricular infarcts are the classic "missed" presentations: a posterior MI shows ST depression in V1–V3 rather than elevation, and an isolated RV infarct can present with ST elevation only in V4R. If the reader takes nothing else from this section, take this: a normal first ECG in a patient with ongoing chest pain is a prompt to repeat the study, not a reason to relax.

Once diagnostic ST elevation is confirmed, the next phone call determines everything. The emergency physician activates the cath lab directly for a PCI-capable center, or activates the transfer-and-lyse decision pathway for a non-PCI center.

Aspirin, P2Y12 Inhibition, and Anticoagulation: The Medication Bundle

The medication bundle for early reperfusion is small, fast, and largely generic, and it is the part of care most often delayed by paperwork.

Aspirin is given as a chewed non-enteric-coated dose of 162 to 325 mg at first contact; the 2023 ACC/AHA chronic coronary disease guideline and the acute coronary syndrome guidelines both endorse this, and there is no reason to wait for the cath lab. A P2Y12 inhibitor is added in most STEMI patients undergoing primary PCI, with ticagrelor 180 mg or prasugrel 60 mg preferred over clopidogrel 600 mg in patients without contraindications. Prasugrel is avoided in patients with prior stroke or transient ischemic attack and in those at high bleeding risk.

Anticoagulation is started in parallel: unfractionated heparin with a weight-based bolus and infusion, or enoxaparin, or bivalirudin, chosen per local protocol. The choice often depends on bleeding risk, renal function, and whether the patient is going to the cath lab or receiving fibrinolysis. For fibrinolysis, the anticoagulant must be appropriate to the chosen lytic agent, and the combination is spelled out in the ESC and ACC/AHA STEMI documents.

One practical point that top-ranking pages tend to skip: the P2Y12 decision frequently hinges on the cath lab's ability to give the drug on the table, and many centers now give aspirin and heparin prehospital but defer the P2Y12 loading dose until coronary anatomy is known in patients with uncertain diagnosis. That is a legitimate protocol variation, not a failure to treat, and it depends on the institution's bleed rates and door-to-balloon times.

Oxygen, Nitrates, and Analgesia: What to Give and What to Withhold

Supplemental oxygen is not routine. It is indicated for hypoxemia, generally a saturation below 90 percent, and routine high-flow oxygen in normoxic patients has been associated with larger infarct size in randomized trials, most notably the DETO2X-AMI trial published in the New England Journal of Medicine in 2017. That trial randomized 6,629 patients and found no mortality benefit from routine oxygen, which is why current guidelines restrict it.

Nitroglycerin relieves ischemic pain and reduces preload, and it is appropriate for ongoing chest pain, hypertension, or heart failure in the absence of contraindications. The contraindications are the ones that get tested on exams and missed in real life: systolic blood pressure below 90 mmHg, suspected right ventricular infarction, recent phosphodiesterase-5 inhibitor use within 24 hours (48 hours for tadalafil), and severe aortic stenosis.

Morphine is used for refractory pain and for pulmonary edema, but observational data have raised questions about its association with delayed P2Y12 absorption and worse outcomes, so many protocols now reserve it for patients whose pain does not respond to nitrates. Pain control matters for catecholamine drive, but the drug is not free of consequence.

For analgesia in patients who cannot tolerate nitrates, fentanyl is often used in the cath lab because of its rapid onset and hemodynamic stability, though the same absorption concern applies. The bottom line: oxygen for hypoxemia, nitrates for ischemia with a pressure to spare, and opioids sparingly.

Reperfusion Strategy Selection: Primary PCI Versus Fibrinolysis

The choice between primary PCI and fibrinolysis is determined by time, geography, and contraindications, and the decision is usually made in the first 10 to 15 minutes after the ECG.

The table compresses what the guidelines say at length. The 2023 ESC ACS guideline retains the 120-minute transfer threshold for PCI over fibrinolysis, and the ACC/AHA STEMI guideline uses the same 90- and 120-minute framework. What changes with geography is the "PCI-capable" definition: a hospital with a cath lab but no on-site surgery may still be PCI-capable for primary PCI under the ACC/AHA framework, and that distinction changes transfer decisions.

One nuance the table cannot hold: patients presenting after 12 hours without ongoing ischemia generally do not benefit from urgent reperfusion of an occluded artery, and the decision shifts to medical therapy and ischemia-guided workup. Patients with ongoing symptoms, shock, or electrical instability are the exception and go to the lab regardless of the clock.

Prehospital and Emergency Department Handoff: The Parallel Processing Checklist

The most reliable way to hit the 90-minute target is to run tasks in parallel rather than in sequence, and that requires a checklist that names who does what.

1: Obtain and interpret the 12-lead ECG within 10 minutes; repeat if nondiagnostic and symptoms persist. 2: Establish two large-bore IVs and draw troponin, electrolytes, renal function, coagulation studies, and a complete blood count. 3: Give aspirin 162–325 mg chewed and start anticoagulation per protocol. 4: Administer oxygen only if saturation is below 90 percent; give nitrates if pressure allows. 5: Activate the cath lab or the transfer/lysis pathway immediately after ECG interpretation, before labs return. 6: Obtain informed consent and prepare the groin or radial access site; document allergies, prior contrast reactions, and renal function. 7: Hand off with a structured report: symptom onset time, ECG findings, medications given with times, allergies, and access site plan.

The failure-handling close: if the cath lab is unavailable, if the patient is too unstable to transfer, or if the ECG diagnosis is uncertain, the pathway shifts to the fibrinolysis checklist or to a repeat ECG and observation. A parallel process that stalls on a missing lab result is a process failure, not a patient problem.

Antithrombotic and Anti-Ischemic Adjuvants in the First Hour

Beta-blockers, statins, and angiotensin-converting enzyme inhibitors are part of the early package, but their timing is more conditional than the headline medications.

Oral beta-blockade is recommended within 24 hours for patients without contraindications, which include heart failure, cardiogenic shock, bradycardia, heart block, and reactive airway disease. Intravenous beta-blockade is reserved for specific hypertensive or tachycardic patients and carries a risk of cardiogenic shock if given too enthusiastically. The COMMIT trial, published in the Lancet in 2005 with 45,852 patients, showed that early IV then oral metoprolol reduced reinfarction and ventricular fibrillation but increased cardiogenic shock, which is why the drug is not routine in unstable patients.

High-intensity statin therapy is started early, often in the emergency department, because the benefit accrues over years but the discharge prescription depends on it. Atorvastatin 80 mg or rosuvastatin 20–40 mg are common choices, and the 2022 ACC/AHA cholesterol guideline supports early initiation in ACS.

An ACE inhibitor or angiotensin receptor blocker is usually started within 24 hours in patients with hypertension, diabetes, heart failure, or reduced ejection fraction, and the first dose is often given after the patient is stable and has adequate renal function. The early anti-ischemic package is therefore not a single order set; it is a sequence with conditional branches.

Cath Lab Preparation and the Handoff That Prevents Delay

Preparing the patient for the cath lab is a logistics intervention as much as a clinical one, and it is where the 90-minute target is most often lost.

Radial access is preferred over femoral access in most STEMI patients because of lower access-site bleeding and mortality in randomized trials, and the 2018 MATRIX trial published in the Lancet enrolled 8,404 patients and supported radial access as the default. That means the pre-procedure prep includes bilateral radial artery assessment and avoidance of unnecessary arterial punctures in the radial arteries.

Consent, allergy documentation, and renal function review happen before the patient leaves the emergency department, and the cath lab team needs to know the contrast volume risk, the prior contrast reactions, and whether the patient is on anticoagulation. A patient with severe chronic kidney disease may need hydration protocols and a contrast-sparing strategy, which is a conversation to start before the table, not on it.

The handoff report should be a structured, 30-second summary: symptom onset, ECG findings, medications with times, access site, allergies, renal function, and any advance care planning documents. The receiving interventionalist should be able to repeat back the plan before the patient rolls.

Special Populations: Renal, Elderly, and Cardiogenic Shock Patients

Three groups change the pre-reperfusion checklist materially, and the changes are not cosmetic.

Renal impairment affects contrast choice, anticoagulant dosing, and the decision about hydration. The 2021 ACC/AHA coronary revascularization guideline and the ESC documents both emphasize risk stratification for contrast-induced acute kidney injury, and the pre-procedure checklist should include a recent creatinine and a plan for minimal contrast volume. Metformin is often held around contrast administration in patients with renal impairment, per local protocol, though the evidence for routine holding is debated.

Elderly patients carry higher bleeding risk and atypical presentations, and the pre-reperfusion bundle should account for frailty, polypharmacy, and prior stroke. Prasugrel is generally avoided in patients aged 75 or older and in those with low body weight, per the drug's label and the TRITON-TIMI 38 trial framework, so ticagrelor or clopidogrel becomes the default in many of these patients.

Cardiogenic shock is the highest-stakes modifier: these patients go to the cath lab regardless of time delay, and the pre-reperfusion bundle includes vasopressors, careful fluid management, and often mechanical circulatory support discussions. The CULPRIT-SHOCK trial, published in the New England Journal of Medicine in 2017, found that culprit-lesion-only PCI reduced death or severe renal failure compared with multivessel PCI in shock, which informs the interventional plan rather than the pre-procedure medications.

Common Delays, Errors, and How to Avoid Them

Most failed reperfusion timelines are not caused by complex medicine. They are caused by a small number of recurring delays.

The first is ECG delay. A patient who arrives by private car and waits in triage for 20 minutes before the first tracing loses a fifth of the 90-minute window before anyone has made a diagnosis. The fix is a triage protocol that obtains the ECG at the door for any chest pain or anginal equivalent.

The second is the "wait for labs" trap. Troponin, creatinine, and coagulation results are useful, but the ECG and the clinical picture drive the reperfusion decision, and waiting for a troponin that will not change management is a pure loss. Guidelines are explicit that the cath lab activation should not wait on biomarkers.

The third is the P2Y12 timing debate. Some centers give the loading dose prehospital, some give it in the emergency department, and some defer it to the cath lab. Each choice has a rationale, and the failure mode is inconsistency rather than any single choice. A center that gives it prehospital should have a bleeding protocol; a center that defers should not be surprised by a longer time to platelet inhibition.

The fourth is the consent and transfer delay at non-PCI centers. A spoke hospital that spends 25 minutes on transfer paperwork after deciding to transfer has eaten the entire margin. The fix is a pre-arranged transfer agreement with a single call activation.

FAQ

What is the single most time-critical intervention in ACS reperfusion?

The 12-lead ECG within 10 minutes of first medical contact is the most time-critical single step, because every downstream decision depends on it. A door-to-ECG time above 10 minutes delays cath lab activation by the same amount. The target is measured from first medical contact, not from triage or from the emergency physician's evaluation. If your institution tracks only door-to-balloon, it is missing the earlier interval where most of the loss occurs.

Can fibrinolysis be given in the emergency department without a cardiologist?

Yes, in many systems fibrinolysis is given by emergency physicians under a protocol when PCI is not available within 120 minutes and there are no contraindications. The ESC and ACC/AHA frameworks support this with a checklist that covers absolute and relative contraindications, including prior intracranial hemorrhage, recent stroke, active bleeding, and severe uncontrolled hypertension. The follow-up is a transfer to a PCI center for rescue or routine angiography, typically within 2 to 24 hours depending on the protocol.

Is routine oxygen harmful in a normal-oxygen patient?

The DETO2X-AMI trial randomized 6,629 patients and found no mortality benefit from routine oxygen in patients without hypoxemia, and some observational data suggest harm at high flow rates. Current guidelines therefore restrict oxygen to patients with saturation below 90 percent or with breathlessness and signs of hypoxemia. The practical failure case is a patient with a saturation of 95 percent who receives 15 liters by non-rebreather for comfort and develops hyperoxia and coronary vasoconstriction.

What is the difference between door-to-balloon and first-medical-contact-to-device time?

Door-to-balloon measures the hospital's internal speed, while first-medical-contact-to-device time captures the whole system, including EMS transport and the time before arrival. The 90-minute guideline target is defined from first medical contact, which is why EMS-based ECG and prehospital activation matter so much. A hospital with a 60-minute door-to-balloon time can still fail the 90-minute target if the patient waited 45 minutes at home or in triage.

How is a P2Y12 inhibitor chosen when the patient is going to the cath lab?

Ticagrelor and prasugrel are preferred over clopidogrel in most STEMI patients undergoing primary PCI, based on the PLATO and TRITON-TIMI 38 trials. Prasugrel is avoided in patients with prior stroke or TIA and is generally not used in patients aged 75 or older or weighing under 60 kg. Clopidogrel remains the choice when bleeding risk is high, when the patient is on anticoagulation, or when the other agents are unavailable.

Do patients who arrive after 12 hours still get urgent reperfusion?

Patients with ongoing ischemic symptoms, cardiogenic shock, or electrical instability still go to the cath lab regardless of the 12-hour mark. For stable patients presenting after 12 hours without ongoing ischemia, urgent reperfusion of an occluded artery does not improve outcomes in most trials, and the management shifts to medical therapy and ischemia-guided evaluation. The total ischemic time and the presence of collateral flow influence the decision in borderline cases.

What should be on the pre-cath-lab checklist for a patient with known kidney disease?

The checklist should include a recent creatinine and estimated glomerular filtration rate, a documented contrast allergy history, a hydration plan, and a contrast-sparing strategy with the interventionalist. Metformin is typically held around contrast in patients with significant renal impairment per local protocol, though practice varies. The 2021 ACC/AHA revascularization guideline and the ESC documents both emphasize risk stratification for contrast-induced acute kidney injury rather than a single universal protocol.

Does radial access really change outcomes compared with femoral access?

The MATRIX trial, published in the Lancet in 2018 with 8,404 patients, found that radial access reduced major bleeding and all-cause mortality compared with femoral access in ACS. The benefit is largest in patients at high bleeding risk and in centers with experienced radial operators. The failure case is a low-volume radial operator who converts to femoral after multiple attempts, which can prolong the procedure and increase complications.

This article is general educational information about acute coronary syndrome and reperfusion therapy. It is not a diagnosis, a treatment plan, or a substitute for the judgment of a qualified clinician who knows the patient. If you or someone else is experiencing chest pain, shortness of breath, or other signs of a heart attack, call your local emergency number immediately; in the United States that is 911, and equivalent emergency and crisis services exist in other countries.